Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
10 | 4 | IMMUNOLOGY//TRANSPLANTATION//RHEUMATOLOGY | 1369268 |
412 | 3 | MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NEUROMYELITIS OPTICA | 30721 |
55 | 2 | MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NEUROMYELITIS OPTICA | 29650 |
18148 | 1 | DACLIZUMAB//NEUROIMMUNOL DIS UNIT//ALEMTUZUMAB | 590 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | DACLIZUMAB | authKW | 344155 | 6% | 20% | 33 |
2 | NEUROIMMUNOL DIS UNIT | address | 340173 | 2% | 58% | 11 |
3 | ALEMTUZUMAB | authKW | 321516 | 10% | 10% | 61 |
4 | OCRELIZUMAB | authKW | 320491 | 2% | 50% | 12 |
5 | MULTIPLE SCLEROSIS | authKW | 184772 | 46% | 1% | 274 |
6 | MS CLIN CENT TEXAS | address | 142443 | 1% | 67% | 4 |
7 | ANTI B CELL AGENTS | authKW | 106834 | 0% | 100% | 2 |
8 | CHARCOT LECTURE | authKW | 106834 | 0% | 100% | 2 |
9 | DAC HYP | authKW | 106834 | 0% | 100% | 2 |
10 | IGGOB | authKW | 106834 | 0% | 100% | 2 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Clinical Neurology | 6140 | 44% | 0% | 262 |
2 | Immunology | 2172 | 30% | 0% | 175 |
3 | Neurosciences | 1638 | 32% | 0% | 187 |
4 | Pharmacology & Pharmacy | 127 | 11% | 0% | 65 |
5 | Medicine, Research & Experimental | 95 | 6% | 0% | 35 |
6 | Psychiatry | 19 | 3% | 0% | 19 |
7 | Medicine, General & Internal | 19 | 4% | 0% | 26 |
8 | Transplantation | 5 | 1% | 0% | 6 |
9 | Biochemical Research Methods | 4 | 2% | 0% | 11 |
10 | Pathology | 3 | 1% | 0% | 8 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | NEUROIMMUNOL DIS UNIT | 340173 | 2% | 58% | 11 |
2 | MS CLIN CENT TEXAS | 142443 | 1% | 67% | 4 |
3 | KLIN NEUROL ENTZUNDLICHE ERKRANKUNGEN NERVENSYST | 71221 | 0% | 67% | 2 |
4 | NIH HUMAN IMMUNOL CHI | 71221 | 0% | 67% | 2 |
5 | CLIN NEUROIMMUNOL | 64500 | 4% | 6% | 21 |
6 | ANALYT DEV QC | 53417 | 0% | 100% | 1 |
7 | BARTS HLTH NHS HLTH SERV TRUST | 53417 | 0% | 100% | 1 |
8 | BIOANA | 53417 | 0% | 100% | 1 |
9 | BIOMED HOSP | 53417 | 0% | 100% | 1 |
10 | CELLULAR IMMUNOTHER Y PHARMACEUT S | 53417 | 0% | 100% | 1 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | MULTIPLE SCLEROSIS JOURNAL | 20358 | 5% | 1% | 31 |
2 | THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 19409 | 1% | 5% | 8 |
3 | JOURNAL OF NEUROIMMUNOLOGY | 13081 | 7% | 1% | 41 |
4 | ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 9481 | 1% | 2% | 8 |
5 | MULTIPLE SCLEROSIS AND RELATED DISORDERS | 7650 | 1% | 2% | 8 |
6 | LANCET NEUROLOGY | 4939 | 2% | 1% | 11 |
7 | ANNALS OF NEUROLOGY | 2424 | 3% | 0% | 19 |
8 | EXPERT REVIEW OF NEUROTHERAPEUTICS | 2419 | 1% | 1% | 7 |
9 | CURRENT OPINION IN NEUROLOGY | 2111 | 2% | 0% | 9 |
10 | CLINICAL IMMUNOLOGY | 1912 | 2% | 0% | 10 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | DACLIZUMAB | 344155 | 6% | 20% | 33 | Search DACLIZUMAB | Search DACLIZUMAB |
2 | ALEMTUZUMAB | 321516 | 10% | 10% | 61 | Search ALEMTUZUMAB | Search ALEMTUZUMAB |
3 | OCRELIZUMAB | 320491 | 2% | 50% | 12 | Search OCRELIZUMAB | Search OCRELIZUMAB |
4 | MULTIPLE SCLEROSIS | 184772 | 46% | 1% | 274 | Search MULTIPLE+SCLEROSIS | Search MULTIPLE+SCLEROSIS |
5 | ANTI B CELL AGENTS | 106834 | 0% | 100% | 2 | Search ANTI+B+CELL+AGENTS | Search ANTI+B+CELL+AGENTS |
6 | CHARCOT LECTURE | 106834 | 0% | 100% | 2 | Search CHARCOT+LECTURE | Search CHARCOT+LECTURE |
7 | DAC HYP | 106834 | 0% | 100% | 2 | Search DAC+HYP | Search DAC+HYP |
8 | IGGOB | 106834 | 0% | 100% | 2 | Search IGGOB | Search IGGOB |
9 | IMMUNOGLOBULIN G THERAPEUTIC USE | 106834 | 0% | 100% | 2 | Search IMMUNOGLOBULIN+G+THERAPEUTIC+USE | Search IMMUNOGLOBULIN+G+THERAPEUTIC+USE |
10 | CD52 | 83565 | 2% | 12% | 13 | Search CD52 | Search CD52 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |